Suppr超能文献

通过原子力显微镜观察到 annexin A5 在天然磷脂双层膜上的结晶体外模型。

In vitro model of annexin A5 crystallization on natural phospholipid bilayers observed by atomic force microscopy.

机构信息

Division of Internal Medicine, Department of Rheumatology, University Medical Centre, Vodnikova cesta 61, SI-1000, Ljubljana, Slovenia.

出版信息

Autoimmunity. 2009 Aug;42(5):414-23. doi: 10.1080/08916930902785371.

Abstract

Annexin A5 is a potent anticoagulant protein with a thrombomodulatory function. It is frequently mentioned with systemic inflammatory autoimmune disease, which share higher vulnerability to cardiovascular diseases. The protein has the ability to bind to membranes containing negatively charged phospholipids in a calcium-dependent manner. The potent anticoagulant properties of the protein are a consequence of this crystallization, which forms the lattice of annexin A5 over phospholipid surface, blocking its availability for coagulation reactions. Crystallization of annexin A5 has been proven on homogeneous synthetic phospholipids. However, the crystallization of annexin A5 on inhomogeneous, naturally derived phospholipid surfaces, in p3 and p6 crystal form, has now been reported for the first time. Atomic force microscopy was chosen for the observation of the crystallization of annexin A5 on different solid supported phospholipid bilayers. In this study model, the optimal results were obtained by using: 0.5 mg/ml lipid vesicles suspension (70% phosphatidylcholine, 30% phosphatidylserine) in HEPES buffer saline (HBS) with 2 mM CaCl(2), large unilamellar vesicles with sizes around 200 nm, 41 degrees C of phase transition temperature and 21 microg/ml of native annexin A5 in HBS with 2 or 20 mM CaCl(2). Results were evaluated by imaging and force measurements. Demonstration that native annexin A5 is able to spontaneously crystallize on naturally derived, inhomogeneous phospholipids is supporting the putative role of annexin A5 crystal structures as possible antithrombotic shield. This in vitro system is probably more appropriate for studying the pathogenetic role of antiphospholipid antibodies.

摘要

膜联蛋白 A5 是一种具有血栓调节功能的强效抗凝蛋白。它常与全身性炎症性自身免疫性疾病相关联,这些疾病更容易发生心血管疾病。该蛋白能够以依赖于钙离子的方式与含有带负电荷的磷脂的膜结合。该蛋白的强效抗凝特性是由于这种结晶作用所致,该作用在磷脂表面上形成膜联蛋白 A5 的晶格,从而阻止其参与凝血反应。已证明在均相合成磷脂上可以发生膜联蛋白 A5 的结晶。然而,现在首次报道了在非均相的天然衍生磷脂表面上以 p3 和 p6 晶型形成膜联蛋白 A5 的结晶。原子力显微镜被选为观察不同固体支撑磷脂双层上膜联蛋白 A5 结晶的方法。在该研究模型中,通过使用以下方法获得了最佳结果:在 HEPES 缓冲盐水(HBS)中含有 2 mM CaCl2 的 0.5 mg/ml 脂质囊泡悬浮液(70%磷脂酰胆碱,30%磷脂酰丝氨酸),大小约为 200nm 的大单层囊泡,相变温度为 41°C,以及在 HBS 中含有 2 或 20 mM CaCl2 的 21 μg/ml 的天然膜联蛋白 A5。通过成像和力测量来评估结果。证明天然膜联蛋白 A5 能够在天然存在的非均相磷脂上自发结晶,这支持了膜联蛋白 A5 晶体结构作为可能的抗血栓形成屏障的假说。该体外系统可能更适合于研究抗磷脂抗体的致病作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验